AngioDynamics (Nasdaq: ANGO ) reported earnings on April 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Feb. 28 (Q3), AngioDynamics missed slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share dropped. GAAP loss per share dropped.
Gross margins shrank, operating margins increased, net margins expanded.
AngioDynamics logged revenue of $81.6 million. The five analysts polled by S&P Capital IQ looked for sales of $83.0 million on the same basis. GAAP reported sales were 58% higher than the prior-year quarter's $51.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.08. The five earnings estimates compiled by S&P Capital IQ predicted $0.05 per share. Non-GAAP EPS of $0.08 for Q3 were 11% lower than the prior-year quarter's $0.09 per share. GAAP EPS were -$0.03 for Q3 compared to -$0.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 50.5%, 650 basis points worse than the prior-year quarter. Operating margin was 7.2%, 360 basis points better than the prior-year quarter. Net margin was -1.2%, 220 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $86.5 million. On the bottom line, the average EPS estimate is $0.06.
Next year's average estimate for revenue is $338.5 million. The average EPS estimate is $0.34.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 99 members out of 114 rating the stock outperform, and 15 members rating it underperform. Among 30 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 26 give AngioDynamics a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AngioDynamics is outperform, with an average price target of $13.10.
Is AngioDynamics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add AngioDynamics to My Watchlist.